MCID: THY028
MIFTS: 71

Thyroid Cancer

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Cancer

MalaCards integrated aliases for Thyroid Cancer:

Name: Thyroid Cancer 12 76 37 29 55 43 15
Thyroid Carcinoma 12 29 55 6 15 73
Neoplasm of the Thyroid Gland 29 6
Thyroid Neoplasm 12 73
Malignant Neoplasm of Thyroid Gland 12
Malignant Tumour of Thyroid Gland 12
Head and Neck Cancer, Thyroid 12
Malignant Neoplasm of Thyroid 73
Neoplasm of Thyroid Gland 12
Thyroid Gland Neoplasm 12
Thyroid Neoplasms 44

Classifications:



External Ids:

Disease Ontology 12 DOID:1781 DOID:3963
ICD10 33 C73
ICD9CM 35 193
MeSH 44 D013964
SNOMED-CT 68 94098005
KEGG 37 H00032

Summaries for Thyroid Cancer

MedlinePlus : 43 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. It makes hormones that help the body work normally. There are several types of cancer of the thyroid gland. You are at greater risk if you Are between ages 25 and 65 Are a woman Are Asian Have a family member who has had thyroid disease Have had radiation treatments to your head or neck You should see a doctor if you have a lump or swelling in your neck. Doctors use a physical exam, thyroid tests, other blood and imaging tests, and a biopsy to diagnose thyroid cancer. Treatment depends on the type of cancer you have and how far the cancer has spread. Many patients receive a combination of treatments. They may include surgery, radioactive iodine, hormone treatment, radiation therapy, chemotherapy, or targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Thyroid Cancer, also known as thyroid carcinoma, is related to thyroid cancer, nonmedullary, 2 and thyroid cancer, nonmedullary, 1, and has symptoms including tinnitus, snoring and coughing. An important gene associated with Thyroid Cancer is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Thyroid cancer and Transcriptional misregulation in cancer. The drugs Cometriq and Lenvima have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.

Wikipedia : 76 Thyroid cancer is cancer that develops from the tissues of the thyroid gland. It is a disease in which... more...

Related Diseases for Thyroid Cancer

Diseases related to Thyroid Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 545)
# Related Disease Score Top Affiliating Genes
1 thyroid cancer, nonmedullary, 2 34.6 BRAF HRAS NRAS PIK3CA RET
2 thyroid cancer, nonmedullary, 1 34.0 BRAF GAS5 H19 HOTAIR MALAT1 PTCSC3
3 thyroid carcinoma, familial medullary 33.6 KRAS MALAT1 RET
4 differentiated thyroid carcinoma 30.8 BRAF HRAS KRAS NRAS RET
5 cowden disease 30.5 AKT1 PIK3CA RET
6 malignant struma ovarii 30.4 HRAS NRAS RET
7 ovarian germ cell teratoma 30.3 NRAS RET
8 pituitary adenoma 30.3 H19 HOTAIR MALAT1
9 sarcoma 30.2 BRAF HOTAIR HRAS KRAS PIK3CA
10 adrenocortical carcinoma, hereditary 30.2 BRAF H19 NRAS PIK3CA
11 ovary adenocarcinoma 30.2 HRAS KRAS PIK3CA
12 adenocarcinoma 30.1 AKT1 BRAF H19 HRAS KRAS MALAT1
13 benign struma ovarii 30.1 HRAS NRAS RET
14 leukemia, chronic lymphocytic 2 30.1 BRAF HRAS KRAS NRAS
15 neuroblastoma 30.1 AKT1 GAS5 H19 HOTAIR MALAT1 NRAS
16 giant congenital nevus 30.0 HRAS NRAS
17 erdheim-chester disease 30.0 BRAF NRAS PIK3CA
18 adenoid cystic carcinoma 30.0 AKT1 HRAS KRAS PIK3CA
19 brain cancer 30.0 AKT1 BRAF HRAS NRAS PIK3CA
20 melanoma 29.9 BRAF CDKN2B-AS1 GAS5 H19 HOTAIR MALAT1
21 b-cell lymphomas 29.8 GAS5 HOTAIR MALAT1 PVT1
22 squamous cell carcinoma, head and neck 29.8 AKT1 BRAF GAS5 H19 HOTAIR HRAS
23 squamous cell carcinoma 29.8 AKT1 BRAF CDKN2B-AS1 H19 HOTAIR HRAS
24 tongue squamous cell carcinoma 29.8 AFAP1-AS1 AKT1 MALAT1 UCA1
25 laryngeal squamous cell carcinoma 29.8 CDKN2B-AS1 H19 HOTAIR MALAT1
26 glioblastoma 29.8 AKT1 BRAF GAS5 H19 HOTAIR HRAS
27 gastrointestinal stromal tumor 29.7 AKT1 BRAF HOTAIR KRAS
28 medulloblastoma 29.7 AKT1 CDKN2B-AS1 H19 HOTAIR NRAS PIK3CA
29 cholangiocarcinoma 29.5 AFAP1-AS1 AKT1 BRAF H19 KRAS MALAT1
30 kidney cancer 29.5 GAS5 H19 HOTAIR MALAT1 PVT1
31 myeloma, multiple 29.4 AKT1 BRAF GAS5 H19 HOTAIR HRAS
32 lung cancer susceptibility 3 29.2 AFAP1-AS1 AKT1 BRAF CASC2 GAS5 H19
33 breast cancer 29.1 AKT1 BRAF CASC2 CDKN2B-AS1 GAS5 H19
34 esophageal cancer 29.0 AKT1 CASC2 CDKN2B-AS1 GAS5 H19 HOTAIR
35 renal cell carcinoma, nonpapillary 28.9 CASC2 GAS5 H19 HOTAIR MALAT1 PANDAR
36 glioma 28.9 BRAF CASC2 CDKN2B-AS1 GAS5 H19 HOTAIR
37 colorectal cancer 28.9 AFAP1-AS1 AKT1 BRAF CASC2 CDKN2B-AS1 GAS5
38 lung cancer 28.8 AFAP1-AS1 AKT1 BRAF CASC2 CDKN2B-AS1 GAS5
39 prostate cancer 28.8 AKT1 CASC2 CDKN2B-AS1 FALEC GAS5 H19
40 hepatocellular carcinoma 28.7 AFAP1-AS1 AKT1 CASC2 CDKN2B-AS1 FALEC GAS5
41 gastric cancer 28.7 AFAP1-AS1 AKT1 CASC2 CDKN2B-AS1 GAS5 H19
42 anaplastic thyroid cancer 12.6
43 thyroid cancer, nonmedullary, 5 12.5
44 thyroid cancer, nonmedullary, 4 12.4
45 thyroid cancer, nonmedullary, 3 12.4
46 thyroid carcinoma, nonmedullary, with or without cell oxyphilia 12.4
47 thyroid cancer, childhood 12.3
48 mucoepidermoid thyroid carcinoma 12.2
49 multicentric papillary thyroid carcinoma 12.2
50 thyroid carcinoma, hurthle cell 11.9

Comorbidity relations with Thyroid Cancer via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism
Lymphomatous Thyroiditis Postsurgical Hypothyroidism

Graphical network of the top 20 diseases related to Thyroid Cancer:



Diseases related to Thyroid Cancer

Symptoms & Phenotypes for Thyroid Cancer

UMLS symptoms related to Thyroid Cancer:


tinnitus, snoring, coughing, sore throat, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Thyroid Cancer according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.56 HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00106-A-0 10.56 KRAS
3 Decreased viability GR00221-A-1 10.56 AKT1 HRAS KRAS PIK3CA RET NRAS
4 Decreased viability GR00221-A-2 10.56 AKT1 HRAS KRAS PIK3CA RET
5 Decreased viability GR00221-A-3 10.56 AKT1 HRAS NRAS
6 Decreased viability GR00221-A-4 10.56 AKT1 PIK3CA RET BRAF
7 Decreased viability GR00231-A 10.56 RET
8 Decreased viability GR00301-A 10.56 KRAS RET BRAF
9 Decreased viability GR00381-A-1 10.56 KRAS BRAF
10 Decreased viability GR00402-S-2 10.56 AKT1 HRAS KRAS PIK3CA RET BRAF
11 Decreased cell migration GR00055-A-1 9.55 AKT1 BRAF HRAS KRAS PIK3CA
12 Increased cell migration GR00055-A-3 8.92 BRAF HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Thyroid Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 AKT1 BRAF HRAS KRAS NRAS PIK3CA

Drugs & Therapeutics for Thyroid Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cometriq 18 49 CABOZANTINIB S-MALATE Exelixis November 2012
2
Lenvima 18 49 LENVATINIB MESYLATE Eisai February 2015
3
Nexavar 18 49 SORAFENIB TOSYLATE Bayer/Onyx December 2005
4
Sensipar 18 CINACALCET HYDROCHLORIDE Amgen March 2004
5
Vandetanib 18 49 vandetanib AstraZeneca April 2011

Drugs for Thyroid Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
2
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
3
Lenvatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 417716-92-8
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
6
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1 439-14-5 3016
7
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
8
Codeine Approved, Illicit Phase 4 76-57-3 5284371
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
11
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 77-92-9 311
12 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
13 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
14 cadexomer iodine Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Anti-Infective Agents, Local Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Anti-Asthmatic Agents Phase 4,Phase 3
18 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Betamethasone acetate Phase 4
20 Betamethasone benzoate Phase 4
21 Betamethasone Valerate Phase 4 2152-44-5
22 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1,Not Applicable
24 glucocorticoids Phase 4,Phase 1,Phase 2
25 Respiratory System Agents Phase 4,Phase 3
26 Betamethasone-17,21-dipropionate Phase 4
27 Betamethasone sodium phosphate Phase 4
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Analgesics Phase 4,Phase 2,Not Applicable
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Anesthetics Phase 4,Phase 3,Phase 1,Not Applicable
32 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 tyrosine Phase 4,Phase 2,Phase 1
35 Anesthetics, General Phase 4,Phase 1,Not Applicable
36 Citrate Phase 4,Phase 2,Phase 1
37 Adjuvants, Anesthesia Phase 4,Phase 1
38 Analgesics, Opioid Phase 4,Not Applicable
39 Anesthetics, Intravenous Phase 4,Phase 1,Not Applicable
40 Narcotics Phase 4,Not Applicable
41 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable
42 Antipyretics Phase 4
43 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
44 Antitussive Agents Phase 4
45
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
46
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 33069-62-4 36314
47
Nicotinamide Approved, Investigational Phase 3,Phase 2 98-92-0 936
48
Ropivacaine Approved Phase 3,Not Applicable 84057-95-4 175805 71273
49
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
50
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816

Interventional clinical trials:

(show top 50) (show all 638)
# Name Status NCT ID Phase Drugs
1 Radiolabeled Molecules for Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
2 rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
3 Total Thyroidectomy With Harmonic Scalpel® Unknown status NCT00385983 Phase 4
4 Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
5 Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer Completed NCT00604318 Phase 4 rhTSH
6 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4 Thyrogen
7 Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Completed NCT01308320 Phase 4 fentanyl citrate;saline
8 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
9 Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results Completed NCT00858104 Phase 4
10 A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
11 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
12 Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy Recruiting NCT02946918 Phase 4 Levothyroxine
13 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
14 To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
15 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
16 Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy Unknown status NCT01551914 Phase 3
17 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
18 Laser Therapy of Benign Thyroid Nodules Unknown status NCT00150150 Phase 3
19 Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer Completed NCT01083550 Phase 2, Phase 3
20 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
21 The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer Completed NCT00794053 Phase 3
22 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
23 Multicenter Study Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
24 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
25 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients Completed NCT01616316 Phase 2, Phase 3
26 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
27 Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
28 Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy Completed NCT02112370 Phase 3 Ropivacaine with epinephrine injection
29 Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain Completed NCT01126060 Phase 3 Usage of Fibrin sealant
30 Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3
31 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
32 A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes Completed NCT02152371 Phase 3 Dulaglutide;Placebo;Insulin Glargine;Metformin
33 Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules Completed NCT01649206 Phase 3
34 Elastography Interest in the Management of Thyroid Nodules Completed NCT01335828 Phase 2, Phase 3
35 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
36 Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) Recruiting NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
37 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
38 Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer Recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
39 Donafenib in 131I-Refractory Differentiated Thyroid Cancer Recruiting NCT03602495 Phase 3 Donafenib;Placebo
40 A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China Recruiting NCT02966093 Phase 3 Lenvatinib;Placebo
41 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
42 Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) Recruiting NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
43 Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Recruiting NCT01149161 Phase 2, Phase 3
44 Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology Recruiting NCT03498183 Phase 2, Phase 3 MIBI-Tc99m/Iodine-123
45 Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer Active, not recruiting NCT01843062 Phase 3 Selumetinib;Placebo;Radioactive Iodine Therapy
46 Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Active, not recruiting NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
47 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer Active, not recruiting NCT00704730 Phase 3 XL184;Placebo
48 Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer Active, not recruiting NCT02418247 Phase 2, Phase 3 I131;I123
49 An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
50 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) Active, not recruiting NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib

Search NIH Clinical Center for Thyroid Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: thyroid neoplasms

Genetic Tests for Thyroid Cancer

Genetic tests related to Thyroid Cancer:

# Genetic test Affiliating Genes
1 Thyroid Carcinoma 29
2 Thyroid Cancer 29
3 Neoplasm of the Thyroid Gland 29

Anatomical Context for Thyroid Cancer

MalaCards organs/tissues related to Thyroid Cancer:

41
Thyroid, Lymph Node, Lung, Endothelial, Testes, Bone, Prostate

Publications for Thyroid Cancer

Articles related to Thyroid Cancer:

(show top 50) (show all 4333)
# Title Authors Year
1
MicroRNA-1270 modulates papillary thyroid cancer cell development by regulating SCAI. ( 30551495 )
2019
2
Icariin inhibits cell proliferation, migration and invasion by down-regulation of microRNA-625-3p in thyroid cancer cells. ( 30551506 )
2019
3
Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. ( 30557850 )
2019
4
E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer. ( 30365150 )
2019
5
MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway. ( 30387841 )
2019
6
Pituitary 18F-FDG uptake correlates with serum TSH levels in thyroid cancer patients on 18F-FDG PET/CT. ( 30422898 )
2019
7
Thyroid Cancer and Benign Nodules After Exposure In Utero to Fallout From Chernobyl. ( 30445441 )
2019
8
Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. ( 30471649 )
2019
9
A scoring system to predict recurrence in patients with differentiated thyroid cancer. ( 30220101 )
2019
10
Lung Metastasis in Pediatric Thyroid Cancer: Radiological Pattern, Molecular Genetics, Response to Therapy, and Outcome. ( 30272236 )
2019
11
A review on the mechanism of iodide metabolic dysfunction in differentiated thyroid cancer. ( 30287400 )
2019
12
Computer-Aided Diagnostic Technique in 2-Deoxy-2-[18F]fluoro-D-glucose-Positive Thyroid Nodule: Clinical Experience of 74 Non-thyroid Cancer Patients. ( 30336966 )
2019
13
Vitamin D deficiency as a risk factor for thyroid cancer: A meta-analysis of case-control studies. ( 30086436 )
2019
14
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop. ( 30121624 )
2019
15
Antitumor effects of anlotinib in thyroid cancer. ( 30139768 )
2019
16
Activity of ecto-5'-nucleotidase (NT5E/CD73) is increased in papillary thyroid carcinoma and its expression is associated with metastatic lymph nodes. ( 30184475 )
2019
17
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases. ( 30261209 )
2019
18
Fine mapping of 14q13 reveals novel variants associated with different histological subtypes of papillary thyroid carcinoma. ( 30350351 )
2019
19
Long non-coding RNA LINC00152 promotes cell growth and invasion of papillary thyroid carcinoma by regulating the miR-497/BDNF axis. ( 30146756 )
2019
20
High Expression of Yes-activated Protein-1 in Papillary Thyroid Carcinoma Correlates With Poor Prognosis. ( 28682834 )
2019
21
MiR-128 suppresses the growth of thyroid carcinoma by negatively regulating SPHK1. ( 30551451 )
2019
22
Teriparatide Replacement Therapy for Hypoparathyroidism During Treatment With Lenvatinib for Advanced Thyroid Cancer: A Case Report. ( 29867775 )
2018
23
Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review. ( 29963277 )
2018
24
Sphingosine 1-phosphate attenuates MMP2 and MMP9 in human anaplastic thyroid cancer C643 cells: Importance of S1P2. ( 29734379 )
2018
25
How deep is our anxiety during treatment of thyroid cancer? ( 29972434 )
2018
26
CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer. ( 29849821 )
2018
27
mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas. ( 29978611 )
2018
28
Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways. ( 29589394 )
2018
29
Ultrasound features of extranodal extension in the metastatic cervical lymph nodes of papillary thyroid cancer: a case-control study. ( 29951341 )
2018
30
Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of lncRNAs. ( 29967342 )
2018
31
Cost Effectiveness of Routine Laryngoscopy in the Surgical Treatment of Differentiated Thyroid Cancer. ( 29417402 )
2018
32
Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. ( 29534964 )
2018
33
The Outcome of Papillary Thyroid Cancer Associated with Graves' Disease: A Case Control Study. ( 29854383 )
2018
34
Neurotrophin Receptors TrkA, p75<sup>NTR</sup>, and Sortilin Are Increased and Targetable in Thyroid Cancer. ( 29037860 )
2018
35
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. ( 29517106 )
2018
36
Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing? ( 29962733 )
2018
37
Evolution in the management of thyroid cancer: an observational study in two referral centres in Belgium. ( 29431057 )
2018
38
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. ( 29517103 )
2018
39
miR-27b-3p is Involved in Doxorubicin resistance of Human Anaplastic Thyroid Cancer Cells via Targeting PPARI^. ( 29924913 )
2018
40
The Role of Different Molecular Markers in Papillary Thyroid Cancer Patients with Acromegaly. ( 29890543 )
2018
41
MiR-524 inhibits cell proliferation and induces cell apoptosis in thyroid cancer via targeting SPAG9. ( 29949157 )
2018
42
LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals. ( 29426928 )
2018
43
A Case of Pneumothorax after Treatment with Lenvatinib for Anaplastic Thyroid Cancer with Lung Metastasis. ( 29796324 )
2018
44
Bromodomaina89containing proteinA 4 is critical for the antiproliferative and proa89apoptotic effects of gambogic acid in anaplastic thyroid cancer. ( 29717765 )
2018
45
A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model. ( 29932104 )
2018
46
Resveratrol Suppresses the Growth and Enhances Retinoic Acid Sensitivity of Anaplastic Thyroid Cancer Cells. ( 29596381 )
2018
47
Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer. ( 29409119 )
2018
48
Identification of BAG3 target proteins in anaplastic thyroid cancer cells by proteomic analysis. ( 29487711 )
2018
49
Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report. ( 29419687 )
2018
50
Anti-<i>hTERT</i> siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft. ( 29563163 )
2018

Variations for Thyroid Cancer

ClinVar genetic disease variations for Thyroid Cancer:

6 (show top 50) (show all 84)
# Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
2 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
3 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
4 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
5 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
6 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
7 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
8 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
9 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
10 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
11 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
12 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
13 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282
14 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh38 Chromosome 12, 25245348: 25245348
15 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
16 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
17 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
18 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
19 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
20 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
21 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
22 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
23 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
24 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
25 RET NM_020975.5(RET): c.1900T> C (p.Cys634Arg) single nucleotide variant Pathogenic rs75076352 GRCh37 Chromosome 10, 43609948: 43609948
26 RET NM_020975.5(RET): c.1900T> C (p.Cys634Arg) single nucleotide variant Pathogenic rs75076352 GRCh38 Chromosome 10, 43114500: 43114500
27 RET NM_020975.4(RET): c.1902C> G (p.Cys634Trp) single nucleotide variant Pathogenic rs77709286 GRCh37 Chromosome 10, 43609950: 43609950
28 RET NM_020975.4(RET): c.1902C> G (p.Cys634Trp) single nucleotide variant Pathogenic rs77709286 GRCh38 Chromosome 10, 43114502: 43114502
29 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh37 Chromosome 10, 43617416: 43617416
30 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh38 Chromosome 10, 43121968: 43121968
31 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
32 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
33 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
34 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
35 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
36 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
37 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh37 Chromosome 7, 140453133: 140453133
38 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh38 Chromosome 7, 140753333: 140753333
39 KRAS NM_033360.3(KRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
40 KRAS NM_033360.3(KRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs121913240 GRCh38 Chromosome 12, 25227342: 25227342
41 KRAS NM_033360.3(KRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
42 KRAS NM_033360.3(KRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic rs121913240 GRCh38 Chromosome 12, 25227342: 25227342
43 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
44 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh38 Chromosome 12, 25227341: 25227341
45 KRAS NM_033360.3(KRAS): c.38G> T (p.Gly13Val) single nucleotide variant drug response rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
46 KRAS NM_033360.3(KRAS): c.38G> T (p.Gly13Val) single nucleotide variant drug response rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
47 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
48 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh37 Chromosome 3, 178917478: 178917478
49 HRAS NM_005343.3(HRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Likely pathogenic rs121913233 GRCh38 Chromosome 11, 533874: 533874
50 HRAS NM_005343.3(HRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Likely pathogenic rs121913233 GRCh37 Chromosome 11, 533874: 533874

Copy number variations for Thyroid Cancer from CNVD:

7 (show all 22)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48476 11 1 43400000 Gain Thyroid cancer
2 75266 13 18400000 72100000 Loss Thyroid cancer
3 80538 13 93800000 114142980 Loss Thyroid cancer
4 85051 14 37800000 43500000 Copy number FOXA1 Thyroid cancer
5 96631 15 90931472 91045475 Amplificationlicatio n IQGAP1 Thyroid cancer
6 111285 17 35400000 68400000 Gain Thyroid cancer
7 120295 18 23300000 71300000 Loss Thyroid cancer
8 150420 20 1 27100000 Amplification Thyroid cancer
9 151957 20 27100000 62435964 Amplification Thyroid cancer
10 153452 20 37100000 62435964 Gain Thyroid cancer
11 171643 3 170900000 182700000 Gain PIK3CA Thyroid cancer
12 171644 3 170900000 182700000 Gain PIK3CA Thyroid cancer
13 191662 5 1 45800000 Amplification Thyroid cancer
14 191664 5 1 45800000 Gain Thyroid cancer
15 200481 5 55800000 180857866 Gain Thyroid cancer
16 201091 5 65300000 159900000 Amplification Thyroid cancer
17 217036 7 1 158821424 Amplification Thyroid cancer
18 230743 8 1 19100000 Loss Thyroid cancer
19 236403 8 16100000 117700000 Amplification Thyroid cancer
20 236404 8 16100000 146274826 Gain Thyroid cancer
21 261707 X 24900000 59500000 Loss Thyroid cancer
22 303365 21 26028751 26066642 Deletion NRF2 Thyroid cancer

Expression for Thyroid Cancer

Search GEO for disease gene expression data for Thyroid Cancer.

Pathways for Thyroid Cancer

Pathways related to Thyroid Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Thyroid cancer hsa05216
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Thyroid Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 AKT1 BRAF HRAS KRAS NRAS PIK3CA
2
Show member pathways
13.02 AKT1 BRAF HRAS KRAS NRAS PIK3CA
3
Show member pathways
13.02 AKT1 BRAF HRAS KRAS NRAS PIK3CA
4
Show member pathways
13.01 AKT1 BRAF HRAS KRAS NRAS PIK3CA
5
Show member pathways
13 AKT1 BRAF HRAS KRAS NRAS PIK3CA
6
Show member pathways
12.97 AKT1 BRAF HRAS KRAS NRAS PIK3CA
7
Show member pathways
12.94 AKT1 BRAF HRAS KRAS NRAS PIK3CA
8
Show member pathways
12.91 BRAF HRAS KRAS NRAS PIK3CA
9
Show member pathways
12.9 AKT1 HRAS KRAS NRAS PIK3CA
10
Show member pathways
12.89 AKT1 BRAF HRAS KRAS NRAS
11 12.89 AKT1 BRAF HRAS KRAS NRAS PIK3CA
12
Show member pathways
12.87 AKT1 BRAF HRAS KRAS PIK3CA
13
Show member pathways
12.87 AKT1 BRAF HRAS KRAS NRAS PIK3CA
14 12.86 AKT1 BRAF HRAS KRAS NRAS
15
Show member pathways
12.86 AKT1 BRAF HRAS KRAS NRAS PIK3CA
16
Show member pathways
12.83 AKT1 HRAS KRAS NRAS PIK3CA
17
Show member pathways
12.83 AKT1 BRAF HRAS KRAS NRAS
18
Show member pathways
12.83 AKT1 BRAF HRAS KRAS NRAS PIK3CA
19
Show member pathways
12.81 AKT1 BRAF HRAS KRAS NRAS PIK3CA
20
Show member pathways
12.78 AKT1 BRAF HRAS KRAS NRAS
21
Show member pathways
12.77 AKT1 HRAS KRAS NRAS PIK3CA
22
Show member pathways
12.77 AKT1 BRAF HRAS KRAS NRAS
23 12.74 BRAF HRAS KRAS NRAS PIK3CA
24
Show member pathways
12.7 AKT1 HRAS KRAS NRAS PIK3CA
25
Show member pathways
12.7 AKT1 HRAS KRAS NRAS PIK3CA
26
Show member pathways
12.7 BRAF HRAS KRAS NRAS PIK3CA
27
Show member pathways
12.63 BRAF HRAS KRAS NRAS PIK3CA
28
Show member pathways
12.62 AKT1 BRAF HRAS KRAS NRAS PIK3CA
29
Show member pathways
12.6 AKT1 HRAS KRAS NRAS PIK3CA
30 12.58 HRAS KRAS NRAS PIK3CA
31
Show member pathways
12.56 AKT1 BRAF HRAS KRAS NRAS PIK3CA
32
Show member pathways
12.55 AKT1 HRAS KRAS NRAS PIK3CA
33
Show member pathways
12.55 AKT1 HRAS KRAS NRAS PIK3CA
34
Show member pathways
12.54 AKT1 HRAS KRAS NRAS PIK3CA
35
Show member pathways
12.53 AKT1 HRAS KRAS NRAS PIK3CA
36
Show member pathways
12.53 AKT1 BRAF HRAS KRAS NRAS
37 12.53 AKT1 HRAS KRAS NRAS PIK3CA
38
Show member pathways
12.53 AKT1 BRAF HRAS KRAS NRAS PIK3CA
39
Show member pathways
12.51 BRAF HRAS KRAS NRAS
40
Show member pathways
12.51 AKT1 HRAS KRAS NRAS PIK3CA
41
Show member pathways
12.51 AKT1 HRAS KRAS NRAS PIK3CA
42
Show member pathways
12.5 AKT1 BRAF HRAS KRAS PIK3CA
43
Show member pathways
12.49 BRAF HRAS KRAS NRAS PIK3CA
44
Show member pathways
12.45 AKT1 HRAS KRAS NRAS PIK3CA
45
Show member pathways
12.44 AKT1 BRAF KRAS PIK3CA
46
Show member pathways
12.43 AKT1 BRAF HRAS KRAS NRAS
47
Show member pathways
12.42 AKT1 HRAS KRAS NRAS PIK3CA
48
Show member pathways
12.41 AKT1 HRAS KRAS NRAS PIK3CA
49
Show member pathways
12.4 BRAF HRAS KRAS NRAS
50 12.39 HRAS KRAS NRAS PIK3CA

GO Terms for Thyroid Cancer

Biological processes related to Thyroid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.61 AKT1 BRAF PIK3CA
2 Ras protein signal transduction GO:0007265 9.54 HRAS KRAS NRAS
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.5 HRAS KRAS NRAS
4 striated muscle cell differentiation GO:0051146 9.48 AKT1 KRAS
5 negative regulation of macroautophagy GO:0016242 9.46 AKT1 PIK3CA
6 negative regulation of neuron apoptotic process GO:0043524 9.46 BRAF HRAS KRAS PIK3CA
7 anoikis GO:0043276 9.4 AKT1 PIK3CA
8 MAPK cascade GO:0000165 9.35 BRAF HRAS KRAS NRAS RET
9 response to isolation stress GO:0035900 9.26 HRAS KRAS
10 positive regulation of gene expression GO:0010628 9.1 AKT1 BRAF CDKN2B-AS1 HRAS KRAS RET

Molecular functions related to Thyroid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.1 AKT1 BRAF HRAS KRAS NRAS RET

Sources for Thyroid Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....